| Literature DB >> 27841043 |
Jennifer Engler1, Anne Dahlhaus1,2,3, Corina Güthlin1.
Abstract
BACKGROUND: Cancer screening participation rates in Germany differ depending on patients' gender. International studies have found that patient-physician gender concordance fosters recommendation and conducting of cancer screening, and especially cancer screening for women.Entities:
Keywords: General practice/family medicine; cancer screening; gender; oncology; survey
Mesh:
Year: 2016 PMID: 27841043 PMCID: PMC5774290 DOI: 10.1080/13814788.2016.1240166
Source DB: PubMed Journal: Eur J Gen Pract ISSN: 1381-4788 Impact factor: 1.904
Coding of dependent variables for multiple logistic regression.
| Coding | ||
|---|---|---|
| Dependent variable | 1 | 0 |
| (a) Who do you see as responsible for recommending colonoscopy/FOBT/skin cancer screening/PSA testing/digital-rectal examination/mammography/breast palpation/Pap testing? | GP | Specialist |
| (b) Who do you see as responsible for conducting colonoscopy/FOBT/skin cancer screening/PSA testing/digital-rectal examination/mammography/breast palpation/Pap testing? | GP | Specialist |
| (c) To what extent do you recommend screening examinations colonoscopy/FOBT/skin cancer screening/PSA testing/digital-rectal examination/mammography/breast palpation/Pap testing in your practice? | Part of routine practice procedure | Irregularly; never and/or only in special cases |
| (d) How often do you conduct FOBT/skin cancer screening/PSA testing/digital-rectal examination/breast palpation in your practice yourself? | Regularly | Irregularly; never |
Sample description by gender category (numbers do not always add up to 100% due to rounding), P-values relate to chi-square tests for dichotomous items (additional qualification in palliative care, psychotherapy, complementary medicine) and Mann–Whitney U-tests for ordinal data (age, work experience, location of medical practice, practice setting).
| Female GPs | Male GPs | |||||
|---|---|---|---|---|---|---|
| % | % | Sig. | ||||
| Age (years) | ||||||
| Total | 46 | 100 | 90 | 100 | 0.006 | |
| <40 | 6 | 13 | 2 | 2 | ||
| 40–49 | 11 | 24 | 21 | 23 | ||
| 50–59 | 20 | 44 | 27 | 30 | ||
| >59 | 9 | 20 | 40 | 44 | ||
| Work experience (years) | ||||||
| Total | 45 | 100 | 81 | 100 | 0.018 | |
| ≤10 | 13 | 29 | 8 | 10 | ||
| 11–20 | 13 | 29 | 29 | 36 | ||
| 21–30 | 16 | 36 | 28 | 35 | ||
| >30 | 3 | 7 | 16 | 20 | ||
| Location of medical practice (inhabitants) | ||||||
| Total | 49 | 100 | 90 | 100 | 0.066 | |
| ≤5000 | 14 | 29 | 35 | 39 | ||
| >5000–20 000 | 10 | 20 | 23 | 26 | ||
| >20 000–100 000 | 12 | 25 | 19 | 21 | ||
| >100 000 | 13 | 27 | 13 | 14 | ||
| Practice setting | ||||||
| Total | 49 | 100 | 90 | 100 | 0.730 | |
| Single practice | 26 | 53 | 45 | 50 | ||
| Group practice | 23 | 47 | 45 | 50 | ||
| Additional qualification | 49 | 100 | 90 | 100 | ||
| Palliative care | 7 | 14 | 22 | 24 | 0.159 | |
| Psychotherapy | 9 | 18 | 13 | 14 | 0.545 | |
| Complementary medicine | 18 | 37 | 29 | 32 | 0.591 | |
Figure 1.Gender differences in percentage of GPs who rate the cancer screening examination in question as useful or fairly useful, tested by applying the chi-square statistic. *More than 20% of cells in this table have expected cell counts of less than five. Chi-square results may be invalid.
Results of multiple logistic regression on the dependent variables (a) and (b), as well as odds ratios for female (0) versus male (1) gender, adjusted for age, location of practice and additional training in complementary medicine.
| Female GPs | Male GPs | 95%CI for OR | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Valid% | Valid % | Sig. | Odds ratio | Lower | Upper | ||||
| (a) The GP (not a specialist) is responsible for RECOMMENDING the following cancer screening examination | |||||||||
| All genders | |||||||||
| Colonoscopy | 46 (48) | 96 | 80 (85) | 94 | 0.899 | 0.9 | 0.2 | 5.2 | |
| FOBT | 47 (49) | 96 | 84 (85) | 99 | 0.329 | 3.5 | 0.3 | 43.8 | |
| Skin cancer | 45 (47) | 96 | 80 (85) | 94 | 0.767 | .8 | 0.1 | 4.4 | |
| Male-specific | |||||||||
| PSA testing | 30 (49) | 61 | 68 (85) | 80 | 0.014 | 2.9 | 1.2 | 6.8 | |
| Digital-rectal examination | 34 (49) | 69 | 79 (86) | 92 | 0.002 | 5.8 | 1.9 | 17.2 | |
| Female-specific | |||||||||
| Mammography | 15 (49) | 31 | 23 (83) | 28 | 0.708 | .9 | 0.4 | 1.9 | |
| Breast palpation | 25 (49) | 51 | 31 (84) | 37 | 0.171 | .6 | 0.3 | 1.3 | |
| Pap testing | 16 (49) | 33 | 18 (80) | 23 | 0.349 | 0.7 | 0.3 | 1.6 | |
| (b) The GP (not a specialist) is responsible for CONDUCTING the following cancer screening examination | |||||||||
| All genders | |||||||||
| Colonoscopy | 2 (49) | 4 | 9 (90) | 10 | 0.944 | 1.1 | 0.2 | 6.2 | |
| FOBT | 47 (48) | 98 | 86 (88) | 98 | 0.909 | .9 | 0.1 | 10.5 | |
| Skin cancer | 27 (47) | 57 | 71 (87) | 82 | 0.004 | 3.8 | 1.5 | 9.4 | |
| Male-specific | |||||||||
| PSA testing | 20 (48) | 42 | 64 (85) | 75 | 0 | 5.2 | 2.2 | 12.0 | |
| Digital-rectal examination | 25 (48) | 52 | 76 (85) | 89 | 0 | 6.8 | 2.7 | 17.3 | |
| Female-specific | |||||||||
| Mammography | 0 (49) | 0 | 3 (88) | 3 | a | a | a | a | |
| Breast palpation | 10 (48) | 21 | 12 (85) | 14 | 0.035 | 0.3 | 0.1 | 0.9 | |
| Pap testing | 1 (49) | 2 | 3 (88) | 3 | 0.682 | 0.6 | 0 | 7.9 | |
Inflated odds ratio due to cell count n = 0.
Results of multiple logistic regression on dependent variables (c) and (d), as well as odds ratios for female (0) versus male (1) gender, adjusted for age, location of practice and additional training in complementary medicine.
| Female GPs | Male GPs | 95%CI for OR | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Valid % | Valid % | Sig. | Odds ratio | Lower | Upper6 | ||||
| (c) RECOMMENDATION of the following cancer screening examination is part of routine practice procedure. | |||||||||
| All genders | |||||||||
| Colonoscopy | 36 (49) | 74 | 64 (87) | 74 | 0.820 | 1.1 | 0.5 | 2.6 | |
| FOBT | 24 (48) | 50 | 59 (87) | 68 | 0.008 | 3.0 | 1.3 | 6.6 | |
| Skin cancer | 30 (49) | 61 | 61 (86) | 71 | 0.178 | 1.7 | 0.8 | 3.8 | |
| Male-specific | |||||||||
| PSA testing | 25 (49) | 51 | 51 (84) | 61 | 0.106 | 1.9 | 0.9 | 4.0 | |
| Digital-rectal examination | 17 (49) | 35 | 59 (87) | 68 | 0 | 4.5 | 2.0 | 10.1 | |
| Female-specific | |||||||||
| Mammography | 16 (49) | 33 | 18 (83) | 22 | 0.060 | 0.4 | 0.2 | 1.0 | |
| Breast palpation | 23 (49) | 47 | 16 (83) | 19 | 0.003 | 0.3 | 0.1 | 0.6 | |
| Pap testing | 19 (49) | 39 | 20 (78) | 26 | 0.186 | 0.6 | 0.3 | 1.3 | |
| (d) CONDUCT the following cancer screening examination regularly | |||||||||
| All genders | |||||||||
| Colonoscopy | 1 (49) | 2 | 1 (90) | 1 | |||||
| FOBT | 32 (49) | 65 | 76 (90) | 84 | 0.005 | 3.5 | 1.4 | 8.4 | |
| Skin cancer | 30 (49) | 61 | 75 (90) | 83 | 0.003 | 4.0 | 1.6 | 10.2 | |
| Male-specific | |||||||||
| PSA testing | 17 (49) | 35 | 53 (88) | 60 | 0.001 | 3.7 | 1.7 | 8.2 | |
| Digital-rectal examination | 16 (49) | 33 | 70 (90) | 78 | 0 | 7.9 | 3.3 | 18.6 | |
| Female-specific | |||||||||
| Mammography | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | |
| Breast palpation | 8 (49) | 16 | 9 (88) | 10 | 0.194 | 0.5 | 0.1 | 1.5 | |
| Pap testing | 2 (49) | 4 | 1 (88) | 1 | 0.216 | 0.2 | 0 | 2.6 | |
Inflated odds ratio due to low cell counts.